Eribulin – the indications and clinical results

02/2017

MUDr. Zuzana Donátová, MUDr. Drahomíra Kordíková, prof. MUDr. Jitka Abrahámová, DrSc.

Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

SUMMARY

Breast cancer in metastatic stage is considered as incurable disease. About 20% of all patients have distant metastases. The offer of new cytotoxic and biological agents caused prolongation of the overall survival in patients with metastatic disease. Eribulin is considered as the new effective cytotoxic agent for pre-treated patients with locally recurrent and metastatic breast cancer. Continuous research of its use was followed with extension of the indication in treatment of liposarcoma.

KEY WORDS

breast cancer, eribulin, quality of life, liposarcoma